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Abstract
We evaluated whether quantitative PCR (qPCR) and (1 ﬁ 3)-b-D-glucan assays could be used to differentiate Pneumocystis pneumonia
(PCP) from Pneumocystis jirovecii colonization in immunocompromised patients with pulmonary inﬁltrates. A total of 40 bronchoalveolar
lavage samples and 107 induced sputum samples from 147 patients who were suspected of having PCP were obtained for PCR detec-
tion of P. jirovecii. Diagnoses of deﬁnite PCP, probable PCP, pneumonia with P. jirovecii colonization (colonization) and pneumonia with-
out colonization (non-colonization) were made in 11, 42, 15 and 60 patients, respectively. A PCP diagnosis was undetermined in 19
patients. The copy numbers, determined using qPCR, were signiﬁcantly higher in deﬁnite PCP and probable PCP patients than in colo-
nized patients. The area under the receiver-operating characteristic curve (AUC), sensitivity and speciﬁcity for discriminating deﬁnite
PCP from colonization were 0.96, 100.0% and 80.0%, respectively, at a cut-off value of 1300 copies/mL. The values for discriminating
probable PCP from colonization were 0.71, 66.7% and 73.3%, respectively, at a cut-off value of 340 copies/mL. b-D-glucan levels were
signiﬁcantly higher in patients with both deﬁnite PCP and probable PCP than in colonized patients. The AUC, sensitivity and speciﬁcity
for discriminating deﬁnite PCP were 0.91, 100.0% and 80.0%, respectively, at a cut-off value of 15.6 pg/mL. The values for discriminating
probable PCP were 0.78, 76.2% and 73.3%, respectively, at a cut-off value of 6.0 pg/mL. Both qPCR and the b-D-glucan assay displayed
high accuracy for discriminating colonization from deﬁnite PCP and displayed moderate accuracy for discriminating colonization from
probable PCP.
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Introduction
Pneumocystis pneumonia (PCP) is one of the most prevalent
infections in human immunodeﬁciency virus (HIV)-infected
patients [1]. PCP also occurs in non-HIV immunocompro-
mised patients receiving transplantation, immunosuppressive
therapy and antitumour chemotherapeutic agents [2]. The
standard method for laboratory diagnosis of PCP is micro-
scopic visualization of Pneumocystis jirovecii in respiratory sam-
ples, including bronchoalveolar lavage (BAL) or induced
sputum (IS). Non-HIV patients often develop PCP with a
lower fungal burden than that of HIV-infected patients [3],
and this lower fungal burden can result in false-negative
results following microscopic examination [4]. Because of
this problem, polymerase chain reaction (PCR), a highly sen-
sitive technique, has been used for diagnosing PCP. However,
Pneumocystis colonization, deﬁned as the detection of the
organism or its DNA without signs or symptoms of pneumo-
nia, has been reported in several studies [5]. In addition,
some patients with pulmonary inﬁltrates who were PCR-
positive for P. jirovecii have been diagnosed as having pneu-
monia resulting from a different aetiology than PCP, and the
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positive PCR results were considered indicative of coloniza-
tion with P. jirovecii [4–6].
Although a positive conventional PCR result cannot distin-
guish colonization from infection, several studies have shown
that the copy number of the speciﬁc P. jirovecii gene that is
measured using quantitative real-time PCR (qPCR) is signiﬁ-
cantly higher in patients with PCP than in colonized patients
[6–12]. Of the various serum markers tested, it has also
been reported that the serum (1 ﬁ 3)-b-D-glucan (b-D-
glucan) level is the best test for PCP diagnosis [13–16]. To
date, however, only one study [17] with a limited number of
patients has assessed the b-D-glucan assay for discrimination
of PCP from colonization.
In this study, we evaluated whether qPCR and the b-D-
glucan assay could be used to discriminate PCP from coloni-
zation with P. jirovecii in immunocompromised patients with
pulmonary inﬁltrates.
Materials and Methods
Patients and clinical samples
A total of 56 BAL and 161 IS samples from 217 patients sus-
pected of PCP were prospectively obtained for Pneumocystis
PCR at Kyoto University Hospital, a 1182-bed tertiary care
hospital, between January 2008 and December 2010. In cases
in which multiple samples were taken from a patient, the
sample from the ﬁrst episode of PCP was studied. Fifty-six
patients without new ground-glass opacities by chest com-
puted tomography and 14 immunocompetent patients were
excluded. The remaining 147 eligible immunocompromised
patients had new ground-glass opacities and clinical presenta-
tions such as fever, cough, sputum, dyspnoea or leucocytosis.
These patients provided 40 BAL samples and 107 IS samples.
The Ethics Committee of Kyoto University Graduate School
and the Faculty of Medicine approved this study and waived
the need to obtain informed consent from each patient.
Diagnosis of PCP
The diagnosis of deﬁnite PCP was established by the micro-
scopic identiﬁcation of P. jirovecii using Gomori methenamine
silver staining. A diagnosis of probable PCP was made when
the patient did not have microscopically visible P. jirovecii but
had a clinical presentation compatible with PCP, including
complete resolution of pulmonary inﬁltrates after a full
course of anti-PCP treatment [4]. The remaining non-PCP
patients who had positive qPCR results without any signs or
symptoms of PCP and who improved without anti-PCP
treatment were diagnosed as ‘pneumonia with P. jirovecii col-
onization’ (colonization) [5]. Non-PCP patients having nei-
ther observable P. jirovecii nor positive qPCR results were
classiﬁed as ‘pneumonia without P. jirovecii colonization’ (non-
colonization). Patients who had positive PCR results and
pulmonary inﬁltrates that were resolved by a full course of
antimicrobial treatment for concomitant organisms with
anti-PCP drugs or who did not improve with or without
anti-PCP treatment were classiﬁed as undetermined because
it was difﬁcult to discriminate between probable PCP and
colonization for these patients.
Clinical data
The clinical information acquired by a medical chart review
included age, sex, underlying diseases, immunosuppressive
therapies and prophylaxis for PCP during the month prior to
sample collection, clinical symptoms, laboratory values, and
the ﬁnal diagnosis made by the physician. Hypoxia was
deﬁned as an arterial PaO2 < 70 mmHg on room air or a
requirement for supplemental oxygen.
Real-time qPCR
Respiratory samples were centrifuged at 1000 · g for
10 min. The pellet was resuspended in 200 lL of the original
ﬂuid, and DNA was extracted using the QIAamp DNA Mini
kit (Qiagen, Hilden, Germany). DNA was eluted in a ﬁnal
volume of 100 lL. Forward (5¢-CATATGATTCTATATTAA
TGGATGTGGAGA-3¢) and reverse (5¢-TTTATAGCAG
GAATAACTCGAGAAATCT-3¢) primers were designed to
amplify a 142-bp segment of the single-copy dihydropteroate
synthase gene. Real-time PCR for P. jirovecii was performed
in a 25 lL reaction volume containing 0.9 lM of each pri-
mer, 0.25 lM TaqMan probe (5¢-FAM-ATATCAATTATCGT
CGCCC-MGB-3¢), 1 · TaqMan Gene Expression Master Mix
(Applied Biosystems (ABI)), and 5 lL puriﬁed DNA. Thermal
cycling was performed in an ABI PRISM 7000 Sequence
Detection system (ABI) as follows: 2 min at 50C, 10 min at
95C, followed by 50 cycles of 15 s at 95C and 1 min at
60C. Quantiﬁcation was performed using ABI PRISM soft-
ware and was based on the extrapolation of data to standard
curves, which were generated by the ampliﬁcation of a ten-
fold dilution series of a plasmid standard (5–5 · 105 copies/
reaction). To generate the plasmids, the PCR-ampliﬁed prod-
uct was cloned into the pCR-TOPO vector (Invitrogen,
Carlsbad, CA, USA) and sequenced. A copy number of less
than the detection limit of 5 copies/reaction was considered
to be 1 copy/reaction. The quantiﬁed copy numbers of Pneu-
mocystis are expressed as copy numbers per 1 mL of sample.
b-D-glucan assay
Plasma b-D-glucan was measured with the b-glucan test
WAKO (Wako Pure Chemical Industries, Tokyo, Japan).
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Plasma samples were collected prior to the collection of
BAL or IS samples and the initiation of treatment. The assay
was performed at our institution on the same day that the
plasma was obtained.
Statistical analysis
Categorical variables were compared using the Fisher exact
test. Continuous variables were compared using the Kruskal–
Wallis test or the Mann–Whitney U-test. b-D-glucan values
under the detection limit of 4.3 pg/mL were considered to
be 4.3 pg/mL. Receiver-operating characteristic (ROC)
curves for the b-D-glucan levels and copy numbers were con-
structed, and their optimal cut-off values were determined
with the maximum Youden index. We compared the area
under the curve (AUC) of the two ROC curves using the
method described by Delong et al. [18]. A p value <0.05 was
considered statistically signiﬁcant. All statistical analyses were
carried out using Stata version 11.2 (StataCorp, College Station,
TX, USA).
Results
A diagnosis of deﬁnite PCP, probable PCP, colonization, non-
colonization or undetermined was made in 11, 42, 15, 60
and 19 patients, respectively. BAL samples were obtained
from 7, 10, 6, 12 and ﬁve of these patients, respectively.
All deﬁnite patients received anti-PCP treatment. The ﬁnal
diagnoses of the colonized patients included bacterial pneu-
monia (n = 4), interstitial pneumonia (n = 3), invasive asper-
gillosis (n = 2), atypical pneumonia (n = 1), acute respiratory
distress syndrome (ARDS) due to sepsis (n = 1), tuberculosis
(n = 1), pulmonary embolism (n = 1), cryptogenic organizing
pneumonia (n = 1), and pulmonary alveolar proteinosis
(n = 1). Among the non-colonized patients, the ﬁnal diagno-
ses included interstitial pneumonia (n = 18), bacterial pneu-
monia (n = 10), ARDS due to sepsis (n = 9), drug-induced
pneumonia (n = 5), pulmonary haemorrhage (n = 5), viral
pneumonia (n = 3), tuberculosis (n = 2), pulmonary oedema
(n = 1), invasive aspergillosis (n = 1), radiation pneumonitis
(n = 1), lymphangitis carcinomatosa (n = 1), cryptogenic
organizing pneumonia (n = 1), and unknown (n = 3).
Clinical features
Table 1 shows the patient demographics and characteristics.
Three deﬁnite patients and two probable patients had HIV
infection, whereas none of the colonized or non-colonized
patients did. An analysis of laboratory test results revealed
signiﬁcant differences in thrombocyte, C-reactive protein,
blood urea nitrogen and total bilirubin levels between the
four groups.
Real-time qPCR
The qPCR and b-D-glucan assay results are presented in
Fig. 1. All deﬁnite patients and 40 of the 42 probable patients
were qPCR-positive. Copy numbers were signiﬁcantly higher
TABLE 1. Patient demographics and clinical characteristics
Characteristics
Deﬁnite PCP Probable PCP Colonized Non-colonized
p value(n = 11) (n = 42) (n = 15) (n = 60)
Age, years 55 (40–65) 63 (54–69) 65 (54–71) 60 (52–70) 0.52
Male sex 8 (73%) 23 (55%) 7 (47%) 35 (58%) 0.62
Underlying disease
Collagen vascular disease 6 (55%) 26 (62%) 9 (60%) 30 (50%) 0.69
Solid malignancy 0 (0%) 8 (24%) 2 (13%) 19 (32%) 0.08
Haematological malignancy 2 (18%) 7 (17%) 4 (27%) 7 (12%) 0.46
Organ transplantation 0 (0%) 3 (7%) 2 (13%) 8 (13%) 0.58
HIV infection 3 (27%) 2 (5%) 0 (0%) 0 (0%) 0.002
Corticosteroids 7 (64%) 31 (74%) 11 (73%) 43 (72%) 0.93
Immunosuppressive agents
other than corticosteroids
4 (36%) 23 (55%) 7 (47%) 23 (38%) 0.39
Anti-tumour chemotherapy 0 (0%) 10 (24%) 4 (27%) 14 (23%) 0.32
PCP prophylaxis 0 (0%) 2 (5%) 2 (3%) 12 (20%) 0.7
Hypoxia 7 (64%) 26 (62%) 8 (53%) 44 (73%) 0.40
Laboratory ﬁndings
Neutrophils, /mm3 6200 (2400–9600) 6400 (4100–11 100) 56 000 (1400–7800) 6350 (4225–10 600) 0.41
Lymphocytes, /mm3 800 (500–1000) 700 (400–1100) 400 (200–1300) 700 (200–1100) 0.77
Thrombocytes, /mm3 13.8 (12.3–20.9) 20.3 (14.3–30.4) 15.1 (6.3–21.3) 13.1 (4.7–28.7) 0.04
C-reactive protein, mg/dL 3.0 (1.1–6.8) 5.9 (2.7–9.7) 2.4 (0.6–9.7) 8.2 (2.3–15.4) 0.049
Albumin, mg/dL 3.2 (2.6–3.3) 3.1 (2.5–3.4) 2.9 (2.4–3.6) 2.8 (2.3–3.3) 0.70
Creatinine, mg/dL 0.6 (0.5–0.7) 0.7 (0.5–1.4) 0.7 (0.5–1.4) 0.8 (0.5–1.4) 0.41
Blood urea nitrogen, mg/dL 15 (10–16) 18 (12–25) 16 (14–23) 23 (15–36) 0.04
Total bilirubin, mg/dL 0.6 (0.4–0.8) 0.5 (0.4–0.7) 0.7 (0.5–0.8) 0.8 (0.5–1.3) 0.049
Lactate dehydrogenase, IU/L 502 (275–598) 330 (260–428) 323 (277–381) 308 (237–500) 0.50
Data are presented as the n (%) or median (interquartile range). Some patients had two or more underlying diseases or conditions.
PCP, Pneumocystis pneumonia; HIV, human immunodeﬁciency virus.
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in the deﬁnite group (median 460 000 copies/mL, range
1400–15 000 000) than in the colonized group (median 180,
range 10–15 000; p < 0.001). This difference was signiﬁcant
for both BAL (p 0.002) and IS (p 0.02) samples. The ROC
curve (Fig. 2a) measured an AUC of 0.96, a sensitivity of
100.0% and a speciﬁcity of 80.0% for discriminating the deﬁ-
nite group from the colonized group, with a cut-off value of
1300 (Table 2). The copy numbers were also signiﬁcantly
higher in the probable group (median 1300, range 10–
7 100 000) than in the colonized group (p 0.001). When
BAL and IS samples were analysed separately, the difference
was not statistically signiﬁcant (p 0.12 for BAL and p 0.13 for
IS). The AUC, sensitivity and speciﬁcity were reduced to
0.71, 66.7% and 73.3%, respectively, with a cut-off value of
340 (Fig. 2b). The deﬁnite group had signiﬁcantly higher copy
numbers than the probable group (p < 0.001). The copy
numbers were not signiﬁcantly different between the BAL
and IS samples in the deﬁnite and probable groups (p 0.57
and p 0.29, respectively), but they were signiﬁcantly different
in the colonized group (p 0.02). To discriminate the deﬁnite
and probable groups from the colonized group, ROC analysis
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FIG. 1. P. jirovecii copy numbers (a) and b-D-glucan levels (b) accord-
ing to patient group. In the box and whisker plots, the boxes contain
50% of the sample data, with the median value indicated by a hori-
zontal bar. The whiskers contain 1.5 · the interquartile range. (a)
The copy numbers were signiﬁcantly higher in the deﬁnite PCP
group when compared with the colonized group in both BAL and IS
samples. The copy numbers were not signiﬁcantly different between
the BAL and IS samples in the deﬁnite and probable PCP groups
(p 0.57 and p 0.29), but were signiﬁcantly different in the colonized
group (p 0.02). (b) The b-D-glucan levels were signiﬁcantly higher in
both the deﬁnite and probable PCP groups when compared with the
colonized group.
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FIG. 2. Receiver-operator characteristic curves of P. jirovecii copy
numbers and b- D-glucan levels for the diagnosis of PCP. (a) The def-
inite PCP group was compared with the colonized group. The
arrows indicate cut-off values of 15.6 pg/mL for b-D-glucan level and
1300 copies/mL for copy number. (b) The probable PCP group was
compared with the colonized group. The arrows indicate cut-off val-
ues of 6.0 pg/mL for b-D-glucan level and 340 copies/mL for copy
number.
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produced an AUC of 0.76, a sensitivity of 73.6% and a speci-
ﬁcity of 73.3%, with a cut-off value of 1300.
b-D-glucan assay
The b-D-glucan levels were signiﬁcantly higher in the deﬁnite
group (median 39.5 pg/mL, range 15.7–352.7) than in the colo-
nized group (median 4.3, range 4.3–61.5, p < 0.001) and the
non-colonized group (median 4.3, range 4.3–160.4; p < 0.001,
Fig. 1b). The ROC curves (Fig. 2a) produced an AUC of 0.91,
a sensitivity of 100.0% and a speciﬁcity of 80.0% for discrimi-
nating the deﬁnite group from the colonized group and values
of 0.94, 100% and 90.0%, respectively, for discriminating the
deﬁnite group from the non-colonised group, with a cut-off
value of 15.6 (Table 2). Similar to the results obtained for the
deﬁnite group, the b-D-glucan levels were signiﬁcantly higher in
the probable group (median 23.1, range 4.3–1007) than in the
colonized (p 0.001) and non-colonized groups (p < 0.001).
The ROC curves (Fig. 2b) produced an AUC of 0.78, a sensi-
tivity of 76.2% and a speciﬁcity of 73.3% for discriminating the
probable group from the colonized group, and values of 0.81,
76.2% and 83.3%, respectively, for discriminating the probable
group from the non-colonized group, with a cut-off value of
6.0. The b-D-glucan levels were similar between the deﬁnite
and probable groups (p 0.25) and between the colonized and
non-colonized groups (p 0.62). To discriminate the deﬁnite
and probable groups from the colonized and non-colonized
groups, ROC analysis produced an AUC of 0.83, a sensitivity
of 81.1% and a speciﬁcity of 81.3%, with a cut-off value of 6.0.
Among the four patients in the colonized group with a
positive b-D-glucan level (>6.0 pg/mL), two had probable
invasive pulmonary aspergillosis, whereas the others did not
have any detectable fungal infections. Among the ten patients
with positive b-D-glucan levels in the non-colonized group,
one had candidaemia, one had cryptococcaemia, one
received haemodialysis, and four received albumin or intrave-
nous immunoglobulin therapy. The others had no detectable
fungal infections, bacteraemia or treatment with amoxicillin-
clavulanate.
The AUC analyses showed that the qPCR and b-D-glucan
assays had excellent and comparable diagnostic performances
for discriminating the deﬁnite group from the colonized
group (p = 0.38, Fig. 2a). When the probable group was
compared with the colonized group, the diagnostic perfor-
mances of the two assays were also comparable (p 0.40,
Fig. 2b).
Discussion
Previous studies assessing qPCR for the diagnosis of PCP
have targeted various genes and determined various cut-off
values for the discrimination of PCP from colonization [7–
12]. However, the sensitivities (84–100%) and speciﬁcities
(93–100%) of the qPCR assays were sufﬁcient, provided that
positive microscopy results were also obtained [7–9]. We
used the dihydropteroate synthase gene as a PCR target
because it is a single-copy gene in the P. jirovecii genome
[19], which allowed us to show that the copy numbers of
the deﬁnite PCP patients were signiﬁcantly higher than the
copy numbers of the colonized patients, with an excellent
AUC, sensitivity and speciﬁcity. Previous studies have
reported a wide range of qPCR cut-off values that do not
effectively discriminate PCP from colonization, and that
approximately one-third to one-half of PCP patients have a
TABLE 2. Diagnostic performance of P. jirovecii copy numbers and b-D-glucan for PCP detection
Test AUC (95% CI) Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
Copy number
Deﬁnite PCP vs. colonized 0.96 (0.89–1.00) 100.0 80.0 78.6 100.0
Probable PCP vs. colonized 0.71 (0.58–0.85) 66.7 73.3 87.5 44.0
Deﬁnite and probable PCP vs. colonized 0.76 (0.65-0.88) 73.6 73.3 90.7 44.0
b-D-glucan
Deﬁnite PCP vs. colonized 0.91 (0.79–1.00) 100.0 80.0 78.6 100.0
Deﬁnite PCP vs. non-colonized 0.94 (0.88–0.99) 100.0 90.0 64.7 100.0
Deﬁnite PCP vs. colonized and non-colonized 0.93 (0.88–0.99) 100.0 88.0 55.0 100.0
Probable PCP vs. colonized 0.78 (0.65–0.90) 76.2 73.3 88.9 52.4
Probable PCP vs. non-colonized 0.81 (0.72–0.89) 76.2 83.3 76.2 83.3
Probable PCP vs. colonized and non-colonized 0.80 (0.72-0.88) 76.2 81.3 69.6 85.9
Deﬁnite and probable PCP vs. colonized and non-colonized 0.83 (0.76-0.90) 81.1 81.3 75.4 85.9
The cut-off values for copy number were 1300 copies/mL (deﬁnite PCP) and 340 copies/mL (probable PCP and deﬁnite and probable PCP). When the following changes were
made to the cut-off values, the PPV was calculated as follows: 340 copies/mL for deﬁnite PCP (78.6%), 1300 copies/mL for probable PCP (87.5%), and 1300 copies/mL for
deﬁnite and probable PCP (91.4%). The cut-off values for b-D-glucan were 15.6 pg/mL (deﬁnite PCP) and 6.0 pg/mL (probable PCP and deﬁnite and probable PCP). When the
following changes were made to the cut-off values, the PPV was calculated as follows: 6.0 pg/mL for deﬁnite PCP (vs. colonized, 78.6%; vs. non-colonized, 52.4%; vs. colonized
and non-colonized, 44.0%), 15.6 pg/mL for probable PCP (vs. colonized, 89.3%; vs. non-colonized, 80.6%; vs. colonized and non-colonized, 73.5%), and 15.6 pg/mL for deﬁnite
and probable PCP (80.0%).
PCP, Pneumocystis pneumonia; AUC, area under the receiver-operator characteristic curve; CI, conﬁdence interval; PPV, positive predictive value; NPV, negative predictive
value.
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copy number in this range [7–10]. In this study, three of 11
deﬁnite PCP patients had a copy number in this ‘grey zone’
between deﬁnite PCP and colonization.
Although the reference standard for the diagnosis of PCP
is microscopic visualization of P. jirovecii, probable or pre-
sumptive PCP has been deﬁned as compatible with clinical
conditions, and treatment for PCP has commenced without
microbiological ﬁndings in previous studies [4,6,10]. In this
study, we demonstrated that the qPCR results from the
probable PCP patients were signiﬁcantly higher than those
from the colonized patients but were signiﬁcantly lower than
those from the deﬁnite PCP patients. As a result, the AUC
comparing probable PCP with colonized patients was
reduced from 0.96 to 0.71, and the range of copy numbers
fully overlapped.
Several studies have shown that b-D-glucan assays have
92–100% sensitivity and 86–94% speciﬁcity for the diagnosis
of deﬁnite PCP when compared with controls with or with-
out pneumonia [16,20–22]. Damiani et al. [17] examined six
deﬁnite PCP patients and eight colonized patients and found
100.0% sensitivity and 75.0% speciﬁcity. Our study also dem-
onstrated a sensitivity of 100.0% and speciﬁcities of 80.0%
and 90.0% in the discrimination of deﬁnite PCP from non-
PCP with or without colonization, respectively. Del Bono
et al. [23] have reported that b-D-glucan was a reliable mar-
ker for diagnosing presumptive PCP. However, they did not
perform microscopy or PCR, and the colonization status of
their controls was unknown. In contrast, almost all of our
probable PCP patients had positive PCR results, and our
controls were separated into colonized and non-colonized
groups. We found similarly low levels of b-D-glucan in both
control groups. The b-D-glucan assay may be superior to
qPCR for the diagnosis of PCP in terms of the difﬁculties in
collecting respiratory samples, such as the invasiveness of
the procedure and the variability of sample quality. However,
the b-D-glucan assay is not speciﬁc for Pneumocystis and false-
positive results have been reported [24,25].
This study had some limitations. First, we combined the
data from the BAL and IS samples to evaluate the qPCR.
However, when the BAL and IS samples were analysed sepa-
rately, the copy numbers between deﬁnite PCP and colo-
nized patients remained signiﬁcantly different. The copy
numbers were higher in probable PCP patients than in colo-
nized patients, but the difference was not statistically signiﬁ-
cant due to the small number of patients. Second, we had a
small number of deﬁnite PCP patients in this cohort. This
small number was probably because BAL samples were only
obtained from a quarter of all patients, and we used only
Gomori methenamine silver staining to detect P. jirovecii
microscopically; repeated assessments using other stains or
more sensitive ﬂuorescent antibody stains were not per-
formed [26].
In conclusion, we found that a b-D-glucan assay and qPCR
assay both had high accuracies in discriminating deﬁnite PCP
from pneumonia with P. jirovecii colonization. Both the b-D-
glucan and the qPCR assays also had moderate accuracies in
discriminating probable PCP from colonization. These results
suggest that patients who have a clinical presentation and
radiological ﬁndings compatible with PCP and an elevated b-
D-glucan level or an appropriate qPCR copy number may be
categorized as probable PCP patients.
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